Novartis AG ADR (NVS)vsRallybio Corp (RLYB)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
RLYB
Rallybio Corp
$16.88
+0.75%
HEALTHCARE · Cap: $89.88M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 8775906% more annual revenue ($56.69B vs $646,000). RLYB leads profitability with a 7051.0% profit margin vs 22.5%. RLYB trades at a lower P/E of 2.1x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RLYB
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for RLYB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 7051 of every $100 in revenue as profit
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -15.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : RLYB
The strongest argument for RLYB centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 7051.0% and operating margin at -3935.0%.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : RLYB
The primary concerns for RLYB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 49/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rallybio Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, especially within immunology and hematology. The company boasts a promising pipeline of biologic drug candidates that are currently advancing through clinical trials, backed by an experienced management team with significant industry expertise. By forming strategic partnerships, Rallybio enhances its capacity to deliver transformative treatments in underserved therapeutic areas, demonstrating its commitment to improving patient outcomes. With a well-defined strategy and a robust developmental framework, Rallybio is strategically positioned to achieve significant milestones in the healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?